Novavax Global Commercial Operations and COVID-19 Vaccine Update

Robust IgG titers against Omicron sub-variants after primary series with prototype vaccine in COVID-19-infected adults Day 0 and Day 35; n=30; Median age = 61 years Anti-rs IgG Titer GMT (EC50) with 95% CI 1,000,000 100,000 10,000 2,627 1,000 100 1,086 885 949 68x 60x 77x 75x 178,025 65,054 68,425 71,446 10 Prototype BA.1 BA.2 BA.5 Prototype BA.1 BA.2 BA.5 Baseline Day 35 novavax Assay conducted by Novavax Discovery Lab © 2023 NOVAVAX. All rights reserved. 34

View entire presentation